The primary endpoint is the incidence of the composite of arterial access-related complications ( haematoma 5 cm , pseudoaneurysm , arteriovenous fistula , access-site-related bleeding , acute ipsilateral leg ischaemia , the need for vascular surgical/interventional treatment or documented local infection ) at 30 days after randomisation .